Agenda

Demystifying the Oral SERD Landscape for HR+ Breast Cancer

Komal Jhaveri, MD

‍

Audience Q&A

Komal Jhaveri, MD

‍

Novel Antiestrogens for HR+ Breast Cancer: SERMs, PROTACs, SERCAs and Beyond  

Michael A. Danso, MD

‍

Audience Q&A

Michael A. Danso, MD

‍

Emerging Date Guiding Antibody Drug Conjugate Use for HR+ Metastatic Breast Cancer

Kelly E. McCann, MD, PhD

‍

Audience Q&A

Kelly E. McCann, MD, PhD